TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24132867

Group type: EXPERIMENTAL
Intervention: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus methylphenidate (MPH)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: clinical management (CM) including supportive counseling plus methylphenidate (MPH)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: manualized dialectical-behavioral-therapy-based group psychotherapy (GPT) plus placebo (Plac)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: clinical management (CM) including supportive counseling plus placebo (Plac)
Number of subjects: 433
Study: 22342859

Group type: EXPERIMENTAL
Intervention: qPCR diagnosis of aneuploidy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: qPCR diagnosis of euploidy and aneuploidy
Number of subjects: 71
Study: 20670909

Group type: EXPERIMENTAL
Intervention: Double dose of virosomal-adjuvanted influenza vaccine (two doses of 0.50 mL 4 weeks apart)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard dose of virosomal-adjuvanted influenza vaccine (two doses of 0.25 mL 4 weeks apart)
Number of subjects: 65
Study: 17582488

Group type: EXPERIMENTAL
Intervention: Verb-Second clauses
Number of subjects: 19

Group type: COMPARATOR
Intervention: Verb-Final clauses
Number of subjects: 19
Study: 15257437

Group type: EXPERIMENTAL
Intervention: Intraoperative facial monitoring
Number of subjects: 130

Group type: COMPARATOR
Intervention: Surgery without intraoperative facial monitoring
Number of subjects: 130
Study: 12063152

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 50 weeks
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 38 weeks followed by 12 weeks of placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 14 weeks followed by 36 weeks of placebo
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo for 50 weeks
Number of subjects: 395
Study: 9857626

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 7614102

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 255

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 255
Study: 2245435

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg od
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gemfibrozil, 600 mg bid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32861

Group type: EXPERIMENTAL
Intervention: Melperone (100 mg X 3)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Thiothixene (10 mg X 3)
Number of subjects: 81
Study: 30327398

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) after standard chemotherapy, delivered in 15 fractions of 3-4.5 Gy.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) after standard chemotherapy
Number of subjects: 6
Study: 27101789

Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate tissue adhesive
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard suture
Number of subjects: 70
Study: 24680712

Group type: EXPERIMENTAL
Intervention: High intensity training regime
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low intensity training regime
Number of subjects: 44
Study: 21787207

Group type: EXPERIMENTAL
Intervention: Low-dose acitretin (approximately 25 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose acitretin (approximately 50 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20116091

Group type: EXPERIMENTAL
Intervention: Low mood condition (mood induction task)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Previous history of self-harm behaviour
Number of subjects: 38
Study: 18612882

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 86
Study: 16078955

Group type: EXPERIMENTAL
Intervention: Cobblestone mat walking
Number of subjects: 108

Group type: COMPARATOR
Intervention: Regular walking
Number of subjects: 108
Study: 12575301

Group type: EXPERIMENTAL
Intervention: Dengzhanhua injection (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fufangdanshen injection (Group B)
Number of subjects: 100
Study: 10559515

Group type: EXPERIMENTAL
Intervention: NIDDM patients with SI (epsilon(4)/(3) genotype)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: NIDDM patients without SI
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: NIDDM patients with SI (epsilon(4) allele)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: NIDDM patients with epsilon(4)/(3)epsilon(4)/(4) genotype
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (healthy individuals without SI)
Number of subjects: 166

Group type: COMPARATOR
Intervention: NIDDM without SI
Number of subjects: 166
Study: 8528732

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 2210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2210
Study: 1906472

Group type: EXPERIMENTAL
Intervention: Postoperative blood salvage
Number of subjects: 109

Group type: COMPARATOR
Intervention: Banked blood
Number of subjects: 109
Study: 6420046

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum and chemotherapy (C + I)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Chemotherapy alone (C)
Number of subjects: 93
Study: 31277623

Group type: EXPERIMENTAL
Intervention: Smartphone app intervention (n = 54)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Regular intervention for caregivers (n = 54)
Number of subjects: 108
Study: 28789317

Group type: EXPERIMENTAL
Intervention: Laboratory scaled system with randomly varying subapertures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support vector machine based lucky imaging and non-negative matrix factorization based multiframe blind deconvolution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeling of the experimental system
Number of subjects: 0
Study: 26485234

Group type: EXPERIMENTAL
Intervention: Peer-Assisted Multicomponent Behavioral Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-controlled HIV/STI health education and counseling
Number of subjects: 0
Study: 25034347

Group type: EXPERIMENTAL
Intervention: Counter-advertisement
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Control advertisement
Number of subjects: 1269
Study: 22683707

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine (BupTAP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine + Clonidine (CloTAP)
Number of subjects: 90
Study: 20486208

Group type: EXPERIMENTAL
Intervention: Hop intervention (2.04 mg XN, 1.20 mg IX, and 0.1 mg 8‐PN per supplement)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no hop supplements)
Number of subjects: 21
Study: 17509999

Group type: EXPERIMENTAL
Intervention: Telephone and mail survey
Number of subjects: 897
Study: 16160648

Group type: EXPERIMENTAL
Intervention: QGS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ECTb
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LVGTF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LMC
Number of subjects: 20
Study: 11807724

Group type: EXPERIMENTAL
Intervention: AC polysaccharide (MACP) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C conjugate (MCC) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polysaccharide antigens (MACP and MCC)
Number of subjects: 0
Study: 10417495

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7734997

Group type: EXPERIMENTAL
Intervention: One blood sample for total cholesterol (TC) level determination
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Average of two blood samples for total cholesterol (TC) level determination
Number of subjects: 142
Study: 1914366

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin with 64 mg caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6312791

Group type: EXPERIMENTAL
Intervention: Soy polysaccharide (25 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-fiber basal diet (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Soy polysaccharide added to glucose solution
Number of subjects: 14
Study: 30664550

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Supportive Care (SC)
Number of subjects: 127
Study: 27769610

Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome (MetS)
Number of subjects: 5398

Group type: COMPARATOR
Intervention: No Metabolic Syndrome (Control)
Number of subjects: 5398

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (component of MetS)
Number of subjects: 5398

Group type: EXPERIMENTAL
Intervention: Hypertension (component of MetS)
Number of subjects: 5398
Study: 26900640

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 40
Study: 25100134

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day on a 4-week-on-2-week-off schedule
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day continuous dosing
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: HIF-1α low (percent of tumor expression groups 0-2)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: HIF-1α high (percent of tumor expression groups 3-4)
Number of subjects: 292

Group type: COMPARATOR
Intervention: VHL inactivation mechanisms (mutation, methylation, large deletion)
Number of subjects: 292
Study: 18254988

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 11716

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11716
Study: 15121558

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 3
Study: 11049006

Group type: EXPERIMENTAL
Intervention: 0.8 g x kg(‐1) ethanol (EOH) in young subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 mg diazepam (DZ) in young subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.7 g x kg(‐1) ethanol (EOH) in older subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (DZ) in older subjects
Number of subjects: 18
Study: 9313702

Group type: EXPERIMENTAL
Intervention: lexipafant (100 mg/day by continuous intravenous infusion for up to 7 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 12959281

Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg oral dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3552216

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide and hydrocortisone
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 30861038

Group type: EXPERIMENTAL
Intervention: Early AFO provision (week 1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Delayed AFO provision (week 9)
Number of subjects: 33
Study: 28920183

Group type: EXPERIMENTAL
Intervention: Regularly prescribed medications (average 5.6 medications per patient)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: CIRS-G index measures
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Polypharmacy (defined as five or more concurrent medications)
Number of subjects: 503
Study: 26588662

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily with RT plus TMZ and post-RT TMZ
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Concurrent treatment arm
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Maintenance arm
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 26
Study: 24388483

Group type: EXPERIMENTAL
Intervention: Slow eating speed
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fast eating speed
Number of subjects: 70
Study: 23099357

Group type: EXPERIMENTAL
Intervention: MT plus LCSD
Number of subjects: 15

Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LCSD
Number of subjects: 15
Study: 19229603

Group type: EXPERIMENTAL
Intervention: ivabradine therapy initiated at the time of hospital admission
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: ivabradine therapy
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1270
Study: 17437798

Group type: EXPERIMENTAL
Intervention: Maintenance bacillus Calmette-Guerin
Number of subjects: 501

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Cystectomy for T2 or greater disease
Number of subjects: 501
Study: 15046281

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition admixtures exposed to ambient light for 24 hours
Number of subjects: 54

Group type: COMPARATOR
Intervention: Parenteral nutrition admixtures protected from ambient light for 24 hours
Number of subjects: 54

Group type: COMPARATOR
Intervention: Serum MDA concentrations in orally fed healthy neonates
Number of subjects: 54
Study: 11913007

Group type: EXPERIMENTAL
Intervention: 10 weekly sessions about healthy eating followed by 6 weekly sessions about exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 weekly sessions about exercise followed by 10 weekly sessions about healthy eating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 0
Study: 9522325

Group type: EXPERIMENTAL
Intervention: High-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.25 mg levonorgestrel (days 12-21)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Low-levonorgestrel group: 2 mg estradiol valerate (days 1-21) + 0.15 mg levonorgestrel (days 10-21)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: High-levonorgestrel group
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Low-levonorgestrel group
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 210
Study: 7526050

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study: 3117490

Group type: EXPERIMENTAL
Intervention: NORPLANT implants (first set)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: NORPLANT implants (replacement set)
Number of subjects: 376
Study: 29667091

Group type: EXPERIMENTAL
Intervention: Intra-scope channel stent release technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Extra-scope channel release technique
Number of subjects: 41
Study: 27903282

Group type: EXPERIMENTAL
Intervention: START NOW skills training programme (12-week duration)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: START NOW skills training programme
Number of subjects: 128
Study: 24578074

Group type: EXPERIMENTAL
Intervention: mHealth decision-support system (mHealth DSS) for guideline-based screening and management of tobacco use
Number of subjects: 14115
Study: 23759041

Group type: EXPERIMENTAL
Intervention: Vaginal examination (n = 61)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No vaginal examination (n = 74)
Number of subjects: 135
Study: 20961748

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham ultrasound therapy
Number of subjects: 10
Study: 18482017

Group type: EXPERIMENTAL
Intervention: Moisturizer with DNA repair enzymes (Advanced Night Repair Concentrate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated UV-irradiated subjects
Number of subjects: 0
Study: 17286119

Group type: EXPERIMENTAL
Intervention: Familiar faces presented as internal features
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfamiliar faces presented as internal features
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole faces (both familiar and unfamiliar)
Number of subjects: 0
Study: 12654939

Group type: EXPERIMENTAL
Intervention: JPP trials
Number of subjects: 28

Group type: COMPARATOR
Intervention: JCCP trials
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both journals
Number of subjects: 28
Study: 11225746

Group type: EXPERIMENTAL
Intervention: Insulin lispro (Humalog)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Buffered regular human insulin (Velosulin)
Number of subjects: 62
Study: 8962558

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 21
Study: 1444555

Group type: EXPERIMENTAL
Intervention: 5 ml/kg 20% albumin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 ml/kg 4.5% albumin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 ml/kg fresh frozen plasma
Number of subjects: 60
Study: 3989147

Group type: EXPERIMENTAL
Intervention: Anterior rhinomanometry
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Posterior rhinomanometry
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Forced oscillation rhinomanometry
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional rhinomanometric techniques
Number of subjects: 10
Study: 29727479

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 0.4 mg/kg per week
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ciclosporin (CyA) 4 mg/kg per day
Number of subjects: 102
Study: 27553723

Group type: EXPERIMENTAL
Intervention: Left hemisphere anodal-excitatory tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Right hemisphere cathodal-inhibitory tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study: 25237463

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg (group A)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg and solifenacin 5 mg (group B)
Number of subjects: 187
Study: 22169359

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 221

Group type: COMPARATOR
Intervention: Streitberger placebo acupuncture
Number of subjects: 221

Group type: COMPARATOR
Intervention: Mock electrical stimulation
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Empathic consultations
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Practitioner 3
Number of subjects: 221
Study: 19508590

Group type: COMPARATOR
Intervention: Acetylcholine (ACh) infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sodium nitroprusside (NP) infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Norepinephrine (NE) infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Serum C‐reactive protein (CRP) measurement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Serum TNF‐alpha measurement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Serum asymmetric dimethylarginine (ADMA) measurement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Forearm balance of nitric oxide (NO) during ACh infusion
Number of subjects: 32
Study: 18229580

Group type: EXPERIMENTAL
Intervention: Xueshuantong (Panax notoginseng saponins)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Steroid and Xueshuantong
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Steroid, DF‐521 and Xueshuantong
Number of subjects: 62
Study: 15715181

Group type: EXPERIMENTAL
Intervention: Nebulised sidenadet (3mg tid; n = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salbutamol (5mg tid; n = 8)
Number of subjects: 15
Study: 11889308

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (non-septic patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 24
Study: 9817627

Group type: EXPERIMENTAL
Intervention: Fluvoxamine and pindolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluvoxamine and placebo
Number of subjects: 15
Study: 8765697

Group type: EXPERIMENTAL
Intervention: Indomethacin hard-gelatin capsule with saturated polyglycolysed glycerides (Gelucire)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard multiple-unit diffusion-controlled pellet capsule (reference formulation)
Number of subjects: 6
Study: 2501987

Group type: EXPERIMENTAL
Intervention: 123IMP-SPECT
Number of subjects: 49

Group type: COMPARATOR
Intervention: CT scans
Number of subjects: 49

Group type: COMPARATOR
Intervention: IV contrast-enhanced CT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 123IMP-SPECT and CT scans
Number of subjects: 49
Study: 173814

Group type: COMPARATOR
Intervention: Radiation therapy alone (22 patients)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) orally at intervals of 8 weeks (22 patients)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combined radiation and drug therapy (19 patients)
Number of subjects: 63
Study: 31770006

Group type: EXPERIMENTAL
Intervention: Dynamic Boolean models of cellular circuits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized models
Number of subjects: 0
Study: 27609785

Group type: EXPERIMENTAL
Intervention: 20 G vitrectomy plus encircling band (group E1)
Number of subjects: 257

Group type: COMPARATOR
Intervention: 20 G vitrectomy without any buckle (group C)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: 23/25 G vitrectomy without any buckle (group E2)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Best corrected visual acuity
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Spherical refraction shift
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Intraoperative complications
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 257
Study: 26117437

Group type: EXPERIMENTAL
Intervention: Real cerebellar continuous theta burst stimulation (cTBS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham cerebellar continuous theta burst stimulation (cTBS)
Number of subjects: 13
Study: 23186806

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digoxin in patients without HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digoxin in patients with HF
Number of subjects: 0
Study: 21764498

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation training (HFST)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 93